Investor Presentation
102
Investor presentation First six months of 2022
Novo NordiskⓇ
Potential first human dose with cell therapy in collaboration with
Heartseed and others
Utilise internal capabilities and disease understanding
for stem cell development
Internal capabilities
Therapeutic areas
Accelerate innovation through partnerships
iPSC derived cardiomyocyte spheroids
for direct injection into heart
GMP-grade production
capability
my
Academic
collaborations
Ethical stem
cell practices
IP positions on
differentiation protocols
Heartseed
•
Parkinson's disease
First human dose expected first half
of 2022
Chronic heart
2 first human
dose projects
expected in
2022
failure
LUND
UNIVERSITY
Type 1
diabetes
BioLamina
REVOLUTIONIZING CELL CULTURE
Dry age-related
macular degeneration
UCSF
University of California
San Francisco
.
•
•
•
hESC derived dopaminergic progenitor
neurons for placing into the brain
Parkinson's disease
First human dose expected first half of
2022
Novo Nordisk scientists embedded at UCSF lab
Process development, manufacturing, QA/QC,
facilities and operations at Fremont site
GMP: Good manufacturing practice; IP: Intellectual property; iPSC: induced pluripotent stem cells; QA/QC: Combination of quality assurance with quality assurance and quality control; hESC: Human embryonic stem cellView entire presentation